Imago BioSciences (IMGO) : 5-month performance

 

Imago BioSciences (IMGO) to be acquired by Merck (MRK) for $36.00/share

 

 

Imago BioSciences to be acquired by Merck (MRK) for $36.00/share 

• Cos announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.
• “This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,” said Merck Chief Executive Robert Davis in a news release.
• 
  
• Hematology is the branch of medicine that focuses on the study of blood diseases. Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of several bone marrow diseases.

IPOs this week : Aug 9 - 13, 2021 (wk 32)

IPOs expected to price

• Veterinary biotech company PetVivo (PETV) is expected to start trading on August 11. 

IPO quiet period expirations

• F45 Training (FXLV) 
• Membership Collective Group (MCG)
• Phillips Edison & Co (PECO)
• Rapid Micro Biosystems (RPID)
• Sight Sciences (SGHT)
• Blend Labs (BLND)
• Erasca (ERAS),
• Imago Biosciences (IMGO), 
• Stevanato (STVN) 
• Blue Foundry (BLFY). 

IPO lockup expirations

• Signify Health (SGFY)
• Viant Technology (DSP)
• Apria (APR)
• Bumble (BMBL)
• Bioventus (BVS), 
• LoanDepot (LDI), 
• Decibel Therapeutics (DBTX), 
• NexImmune (NEXI) and 
• Talis Biomedical (TLIS).

Imago BioSciences (IMGO) began trading on the Nasdaq on Fri 16 July 21

• Imago BioSciences was founded in 2012 
• HQ in Redwood City, California 
• Hugh Y. Rienhoff, Jr., Founder and Chief Executive Officer

Imago BioSciences priced upsized 8.4 mln share IPO at $16/share, at the high end of the $14-16 expected range
Opened at $17.50.